Bradley Canino
Stock Analyst at Stifel
(1.64)
# 3,456
Out of 5,131 analysts
82
Total ratings
35%
Success rate
-1.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $14.16 | +168.36% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $21.00 | +109.52% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.81 | +433.81% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.35 | +11.11% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $10.90 | +74.31% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $7.99 | +187.86% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $12.07 | +322.54% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $9.41 | +101.91% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $107.51 | -60.93% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $19.68 | +103.25% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $105.05 | +28.51% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.15 | +118.58% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.76 | +468.18% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $3.74 | +167.38% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.14 | +554.21% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $74.77 | -26.44% | 4 | Feb 23, 2024 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $14.16
Upside: +168.36%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $21.00
Upside: +109.52%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.81
Upside: +433.81%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.35
Upside: +11.11%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $10.90
Upside: +74.31%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $7.99
Upside: +187.86%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $12.07
Upside: +322.54%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $9.41
Upside: +101.91%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $107.51
Upside: -60.93%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $19.68
Upside: +103.25%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $105.05
Upside: +28.51%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $9.15
Upside: +118.58%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.76
Upside: +468.18%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.74
Upside: +167.38%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.14
Upside: +554.21%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $74.77
Upside: -26.44%